MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.790
+0.100
+2.13%
After Hours: 4.760 -0.03 -0.63% 17:18 09/21 EDT
OPEN
4.660
PREV CLOSE
4.690
HIGH
4.950
LOW
4.410
VOLUME
445.06K
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
3.130
MARKET CAP
110.28M
P/E (TTM)
-5.6915
1D
5D
1M
3M
1Y
5Y
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marban, Ph.D., Capri...
GlobeNewswire · 09/07 13:00
BRIEF-Capricor Therapeutics To Present Final Data From Duchenne Muscular Dystrophy Phase 2 Trial
reuters.com · 09/02 12:47
Capricor Therapeutics To Present Final Data From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At World Muscle Society 2021
Capricor Therapeutics (NASDAQ:CAPR) ("Capricor" or "the Company"), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and
Benzinga · 09/02 12:35
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS-LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology c...
GlobeNewswire · 09/02 12:30
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 08/19 13:45
SoFi Technologies, Cricut, FIGS among premarket losers' pack
ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sierra...
Seekingalpha · 08/13 12:54
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 08/13 12:08
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CAPR. Analyze the recent business situations of Capricor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CAPR stock price target is 10.50 with a high estimate of 12.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 3.56M
% Owned: 15.44%
Shares Outstanding: 23.02M
TypeInstitutionsShares
Increased
14
302.69K
New
4
71.98K
Decreased
8
907.62K
Sold Out
3
295.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
Frank Litvack
President/Chief Executive Officer/Director
Linda Marban
Chief Financial Officer/Chief Accounting Officer
Anthony Bergmann
Executive Vice President/General Counsel
Karen Krasney
Vice President
Thomas Copmann
Vice President
Houman Hemmati
Vice President
Luis Rodriguez-Borlado
Vice President - Research & Development
Rachel Smith
Other
Deborah Ascheim
Director
Karimah Es Sabar
Director
Joshua Kazam
Independent Director
Earl Collier
Independent Director
George Dunbar
Independent Director
Louis Grasmick
Independent Director
Louis Manzo
Independent Director
David Musket
No Data
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. It consists of cell therapy program, including CAP-1002 with Duchenne muscular dystrophy program and CAP-1002 with COVID-19 (SARS-CoV-2) program. It also includes exosomes program, such as exosome-based vaccines, exosome-based therapeutics and CDC-Derived Exosomes (CAP-2003). Duchenne muscular dystrophy program has completed HOPE-2, a Phase II clinical trial in the United States with its product candidate.CAP-1002 is a cardiac cell derived therapy used to treat patients with late-stage Duchenne muscular dystrophy. The Company has received the United States Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for a clinical study of CAP-1002 in patients with severe or critical COVID-19.

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.